Premas Biotech

We are thrilled to announce that Oravax Medical Inc. a joint venture between Premas Biotech and US based Oramed Pharmaceuticals has received clearance from the South African Health Products Regulatory Authority to commence Phase 1 clinical trials, for its oral COVID-19 vaccine.

Today we celebrate the incredible molecule that carries the blueprint of life — DNA — and the science that helps us decode its secrets. From understanding human evolution to improving healthcare, our research continues to shape the future of medicine and society. We are committed to decode life’s most powerful language and tunring it into real-world impact. @BricDbt @DBTIndia @DrJitendraSingh @rajesh_gokhale @DrSagarSengupta #DNADay #genomics #DNA #biomedicalresearch #CancerGenomics #Populationgenomics #ScienceForSociety #research

We were pleased to host representatives from Premas Biotech for an interaction focused on exploring potential areas of collaboration, identifying shared interests and complementary strengths. It was encouraging to see strong alignment in our vision towards advancing biotechnology and translating research into real-world impact. We look forward to establishing meaningful partnership with them as we move ahead. @DBTIndia @BricDbt @DrJitendraSingh @rajesh_gokhale @DrSagarSengupta @PremasBiotech

#WorldBrainTumorDay Together, we can make a difference! Premas Biotech #Team unites and wishes strength to all the combatants of #BrainTumour, and to their families and friends. Let us all stand together for a future with better treatments and improved outcomes for all.

When biology, technology and brilliant minds converge under one networking umbrella, ideation, collaboration & advancements in biotech sector happen. A glimpse of our participating leaders Dr Prabuddha Kundu, Dr Nupur Mehrotra and Vivek Chandra in action at #BIO2023, Booth 2945.

Premas has developed GMP CRM197, a polysaccharide vaccine carrier using the technology licensed from NRC Canada, through its JV with Glycovax - Espoir Therapeutics. Espoir will focus on development of bio-generic and novel vaccines for infectious diseases. See you at #BIO2023.

We are here at 𝐁𝐢𝐨 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐯𝐞𝐧𝐭𝐢𝐨𝐧! Meet Dr. Prabuddha Kundu, Dr. Nupur Mehrotra and Vivek Chandra to learn more about our breakthrough technologies and vaccine development. #vaccines #boston #biopharmaceuticals #innovation #BIO2023 #partner

Backed by proprietary technologies for difficult-proteins expression system, coupled with PD and manufacturing capabilities for rapid scale up, Premas is able to deliver functional proteins, for therapeutics drugs, antibodies, and vaccines. See you at #Bio2023 in Boston!

At #Bio2023, Premas is showcasing our anti PD-L2 targeting MAb, which has exciting functional data. Our proprietary tech platform was screened to generate the MAb. Looking for collaboration and in-licensing opportunities to accelerate your antibody pipeline -come see us.

At Bio, Premas is showcasing our thermo-stable mRNA-VLP vaccine and therapeutic platform.  If you are looking for collaboration and in-licensing opportunities to accelerate your vaccine and therapeutic candidates that are easy to scale up and are thermo stable, come see us.

Premas is participating in 𝐁𝐢𝐨 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐯𝐞𝐧𝐭𝐢𝐨𝐧, starting on 5th of June in Boston. Do drop by to see us at 𝐁𝐨𝐨𝐭𝐡 2945! #biointernational #boston #biopharmaceuticals #antibody #collaboration #innovation

Shivani Singh joins #PremasBiotech as Head of HR. With 17 years of diverse experience in various sectors, she will lead and develop the future HR roadmap, collaborating closely with the Senior Management Team. We welcome Shivani to the Premas family and wish her the best!

Technology has the power to transform lives and it's a privilege for us to be part of a mission that leverages technology to advance human healthcare and functional protein initiatives. Here’s wishing you all a well-meaning National Technology Day! #NationalTechnologyDay

𝐖𝐨𝐫𝐥𝐝 𝐈𝐦𝐦𝐮𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐖𝐞𝐞𝐤, aims to highlight the collective action needed to protect people from vaccine-preventable diseases. Our latest vaccine technology involves co-expressing mRNA and VLP in host cell for a vaccine with dual specificity immune response.

Our co-founder and MD, Dr. Prabuddha Kundu’s speaker session was a huge success. Thank you everyone who came by and supported us! #thankyou #speaker

We had a great time at #WorldVaccineCongress. Thank you everyone who came by the booth to visit us. It was a pleasure to meet you all. #vaccines #partnership #collaboration #washingtondc

Tomorrow is the last day of #WorldVaccineCongress and if you're coming, be sure to not miss our own Co-founder and Managing Director, Dr. Prabuddha Kundu's interesting presentation on "Rapid Development of Lyophilized VLP - Nucleic Acid Vaccines". #innovation #vaccines

Premas introduces another breakthrough technology: Co-expressing mRNA and VLP in host cell for a vaccine with dual specificity immune response. To learn more, visit us at booth 321 at the #WorldVaccineCongress 2023 in Washington, D.C. #technology #biopharmaceuticals #Vaccines

Premas is a single-stop shop for your Polysaccharide Vaccine development and manufacturing. To learn more, visit us at booth 321 at the #WorldVaccineCongress 2023 in Washington, D.C. #biopharmaceuticals #manufacturing #washingtondc #vaccines #innovation #collaboration

Premas uses its proprietary yeast-based D-CryptTM platform that promises rapid engineering, consistent scale-up and manufacturability. Meet us at booth 321 at the #WorldVaccineCongress, Washington, D.C., to learn more about our vaccine technologies. #engineering #vaccines

Premas is bringing its vaccine development technologies to #WorldVaccineCongress2023. Visit us at Booth 321 to learn how you can accelerate your VLP, VLP + mRNA or Polysaccharide Vaccines, through partnership with us. #development #vaccines #biopharmaceuticals #washington